The SIGMAR1 gene is associated with a risk of schizophrenia and activation of the prefrontal cortex

[1]  J. Deakin,et al.  Alterations in phencyclidine and sigma binding sites in schizophrenic brains Effects of disease process and neuroleptic medication , 1991, Schizophrenia Research.

[2]  H. Ujike,et al.  Sigma (sigma) antagonist BMY 14802 prevents methamphetamine-induced sensitization. , 1992, Life sciences.

[3]  H. Ujike,et al.  Persistent supersensitivity of σ receptors develops during repeated methamphetamine treatment , 1992 .

[4]  Shigeru Okuyama,et al.  Effect of NE-100, a novel σ receptor ligand, on phencyclidine-induced cognitive dysfunction , 1994 .

[5]  M. Jackson,et al.  An N‐terminal double‐arginine motif maintains type II membrane proteins in the endoplasmic reticulum. , 1994, The EMBO journal.

[6]  S. Okuyama,et al.  Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced delayed cognitive dysfunction in rats , 1995, Neuroscience Letters.

[7]  D. Naber,et al.  Efficacy and Safety of an Opiate Sigma-Receptor Antagonist (SL 82.0715) in Schizophrenic Patients with Negative Symptoms: an Open Dose-Range Study , 1996, Pharmacopsychiatry.

[8]  V. Ganapathy,et al.  Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). , 1996, Biochemical and biophysical research communications.

[9]  A. Steiger,et al.  Open clinical trial on the sigma ligand panamesine in patients with schizophrenia , 1997, Psychopharmacology.

[10]  M. Itokawa,et al.  Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia , 1998, Neuroscience Letters.

[11]  Matthias J. Müller,et al.  Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial , 1999, Psychiatry Research.

[12]  M. Huber,et al.  Efficacy and Safety of the Sigma Receptor Ligand EMD 57445 (Panamesine) in Patients with Schizophrenia: an Open Clinical Trial , 1999, Pharmacopsychiatry.

[13]  D. Zamanillo,et al.  Regulation of Ionotropic Glutamate Receptor Subunits in Different Rat Brain Areas by a Preferential Sigma1 Receptor Ligand and Potential Atypical Antipsychotic , 2000, Neuropsychopharmacology.

[14]  T. Terao,et al.  Polymorphisms of the σ1 receptor gene in schizophrenia: An association study , 2000 .

[15]  R. Quirion,et al.  Expression of the purported sigma1 (σ1) receptor in the mammalian brain and its possible relevance in deficits induced by antagonism of the NMDA receptor complex as revealed using an antisense strategy , 2000, Journal of Chemical Neuroanatomy.

[16]  M. Tsuang.  Schizophrenia: genes and environment , 2000, Biological Psychiatry.

[17]  I. Gottesman,et al.  Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. , 2000, American journal of medical genetics.

[18]  S. Takahashi,et al.  Effects of a novel, selective, σ1-ligand, MS-377, on phencyclidine-induced behaviour , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[19]  M. Egan,et al.  Prefrontal neurons and the genetics of schizophrenia , 2001, Biological Psychiatry.

[20]  H. Ujike,et al.  No association between the sigma receptor type 1 gene and schizophrenia: results of analysis and meta-analysis of case-control studies , 2003, BMC psychiatry.

[21]  Teruo Hayashi,et al.  σ-1 Receptor Ligands , 2004 .

[22]  H. Suwaki,et al.  Lack of association between sigma1 receptor gene variants and schizophrenia , 2004, Psychiatry and clinical neurosciences.

[23]  Makoto Ito,et al.  Multichannel near-infrared spectroscopy in depression and schizophrenia: cognitive brain activation study , 2004, Biological Psychiatry.

[24]  S. Higuchi,et al.  Functional polymorphisms in the sigma1 receptor gene associated with alcoholism , 2003, Biological Psychiatry.

[25]  J. Lindenmayer,et al.  A new five factor model of schizophrenia , 2006, Psychiatric Quarterly.

[26]  A. Meyer-Lindenberg,et al.  Intermediate phenotypes and genetic mechanisms of psychiatric disorders , 2006, Nature Reviews Neuroscience.

[27]  Takahisa Taguchi,et al.  Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling. , 2006, Human molecular genetics.

[28]  Yuko Fujita,et al.  Phencyclidine-Induced Cognitive Deficits in Mice are Improved by Subsequent Subchronic Administration of Fluvoxamine: Role of Sigma-1 Receptors , 2007, Neuropsychopharmacology.

[29]  D. Weinberger,et al.  Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia , 2007, Molecular Psychiatry.

[30]  Zhongming Zhao,et al.  Candidate genes for schizophrenia: A survey of association studies and gene ranking , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[31]  C. Spencer,et al.  Identification of loci associated with schizophrenia by genome-wide association and follow-up , 2008, Nature Genetics.

[32]  K. Hashimoto,et al.  Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[33]  J. Entrena,et al.  Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands , 2008, Current neuropharmacology.

[34]  J. Callicott,et al.  Intermediate phenotypes in schizophrenia genetics redux: is it a no brainer? , 2008, Molecular Psychiatry.

[35]  Masato Fukuda,et al.  Reduced frontopolar activation during verbal fluency task in schizophrenia: A multi-channel near-infrared spectroscopy study , 2008, Schizophrenia Research.

[36]  T. Kudo,et al.  TATA Box‐Binding Protein gene is associated with risk for schizophrenia, age at onset and prefrontal function , 2009, Genes, brain, and behavior.

[37]  Sabina M. Gonzales,et al.  Prefrontal activation deficits during episodic memory in schizophrenia. , 2009, The American journal of psychiatry.

[38]  Masao Iwase,et al.  Impaired regional hemodynamic response in schizophrenia during multiple prefrontal activation tasks: A two-channel near-infrared spectroscopy study , 2009, Schizophrenia Research.

[39]  Masato Fukuda,et al.  Association between sigma-1 receptor gene polymorphism and prefrontal hemodynamic response induced by cognitive activation in schizophrenia , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[40]  Michele T. Diaz,et al.  Voxel-based morphometric multisite collaborative study on schizophrenia. , 2009, Schizophrenia bulletin.

[41]  Masato Fukuda,et al.  Association between Catechol-O-Methyltrasferase Val108/158Met Genotype and Prefrontal Hemodynamic Response in Schizophrenia , 2009, PloS one.

[42]  Yuko Fujita,et al.  Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors , 2009, Brain Research.

[43]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[44]  K. Hashimoto,et al.  Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors , 2010, Annals of general psychiatry.

[45]  Takashi Morihara,et al.  The impact of a genome‐wide supported psychosis variant in the ZNF804A gene on memory function in schizophrenia , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[46]  Masao Iwase,et al.  Discriminant analysis in schizophrenia and healthy subjects using prefrontal activation during frontal lobe tasks: A near-infrared spectroscopy , 2010, Schizophrenia Research.

[47]  K. Hashimoto,et al.  Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases , 2010, Annals of general psychiatry.

[48]  K. Ishiwata,et al.  The cholinergic system, sigma-1 receptors and cognition , 2011, Behavioural Brain Research.